Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT03502616
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib — DRUGOral administration twice per day
Study Details
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Key Dates
- Start date
- Jun 7, 2018
- Status verified
- Aug 2021
- Primary completion
- Dec 19, 2019
- Completion
- Aug 20, 2020
Study Design
- Enrollment
- 270 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Tofacitinib
- Placebo Comparator: Placebo
Primary Outcome Measure
Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16 [ Time Frame: Week 16 ]
Locations (28)
Find similar trials in Huntsville, AL
By research site
Rheumatology Associates of North Alabama, PC· Huntsville, ALArizona Arthritis & Rheumatology Associates, P.C.· Gilbert, AZMedvin Clinical Research· Covina, CARheumatology Center of San Diego PC· San Diego, CAUniversity of California, San Francisco Medical Center· San Francisco, CARobin K. Dore, MD, Inc.· Tustin, CA
Related Studies
- Rheumatology Patient Registry and BiorepositoryRecruiting · Yale University · New Haven, Connecticut
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Exactech Shoulder Post Market Clinical Follow-up StudyRecruiting · Exactech · Laguna Woods, California
- IMPACT - AndHealth Autoimmune Research RegistryRecruiting · AndHealth · Columbus, Ohio